Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy.
about
Animals lacking endothelin-converting enzyme-2 are deficient in learning and memory.Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase.Effects of 4-hydroxy-nonenal and Amyloid-beta on expression and activity of endothelin converting enzyme and insulin degrading enzyme in SH-SY5Y cells.Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease.The vascular contribution to Alzheimer's disease.A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injuryN-acetylcysteine prevents 4-hydroxynonenal- and amyloid-beta-induced modification and inactivation of neprilysin in SH-SY5Y cellsThe 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system.Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase.Neurogenesis, Neurodegeneration, Interneuron Vulnerability, and Amyloid-β in the Olfactory Bulb of APP/PS1 Mouse Model of Alzheimer's Disease.Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's diseaseHereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse modelsEffects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells.Beta-amyloid, blood vessels, and brain functionGene therapy in Alzheimer's disease - potential for disease modificationAcyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide.Centella asiatica extract protects against amyloid β1-40-induced neurotoxicity in neuronal cells by activating the antioxidative defence system.Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains.Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease.Complement-associated deposits in the human retinaCan Salivary Acetylcholinesterase be a Diagnostic Biomarker for Alzheimer?Fibrinogen as a key regulator of inflammation in disease.Proteolytic degradation of amyloid β-protein.Huprines for Alzheimer's disease drug development.Metabolite Clearance During Wakefulness and Sleep.Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases.APP mouse models for Alzheimer's disease preclinical studies.A computational view on the significance of E-ring in binding of (+)-arisugacin A to acetylcholinesterase.(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-β42 and thiorphan.The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid-β, and Sleep.Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier
P2860
Q30495123-22E94C78-81C8-42DB-99B7-F473E566EAFFQ33412126-4649F5B8-573F-40EF-81D7-D7ADED2677DCQ33642530-6DC7BD9A-F32B-463A-9F7E-83AC5E69F33AQ33782706-3A8ECCF1-8046-4194-ACAF-EE056BD05E29Q34178526-3AF65D6E-B6D1-4D46-9066-11BFB484F484Q34458328-3612C226-838A-43FF-AAC9-A6D02DA67F26Q34581928-1ABD3A0B-1A70-4F93-B93E-9D437726413EQ36042072-A7439647-E034-4AD3-8FDD-6C43EEC8D990Q36719274-3E0AF7EE-A176-43AC-81C9-61A0801D61F1Q36947147-0A9AFBA4-3D68-40F3-A0E3-F8F285720856Q37178894-0E2F420B-30B2-4534-8E91-DE5BAD16C283Q37188278-0CD17DDD-7488-4F06-A53F-2A145A61F2C8Q37219722-036A72B6-420A-45DF-92D0-BD80E1FADC8FQ37246552-D4C8D1B8-2910-4D55-9069-6946315E0A58Q37295252-8C4E1338-A397-421E-8064-37B3B2619BE7Q37303380-BD76EFC0-D1FA-4FB7-BD32-FAA7DE706D3EQ37346045-E3A3F8E2-16A9-4D77-9CFE-F11661F29A23Q37432185-7F0D5CF8-290B-42A6-8CD7-FA5A98FD01ABQ37596889-4570395C-F2A6-4D66-9096-8CE5CF0D8E17Q37626363-E1C0D445-41A8-4051-BAEE-63E5DF1F085EQ37663763-F0408A80-A244-4DA3-AB5F-2563E9C2132AQ37950860-1D2ABFC4-F41D-4652-8FA4-4744B90B2BE4Q38016899-AC772A16-15EF-4C0B-BE14-7A8584DD8E6AQ38088283-D6480DBE-D099-4C24-97E6-94FC0A993E20Q38661159-AF6880F0-9029-4A21-871E-D96302CADCCCQ38780921-6D822AF1-4CFC-44E7-987A-77787BB3A044Q41582196-4EE73762-E4BA-466E-A993-39F344A0D496Q42148589-57956C10-6CE4-4D70-B94A-B78680AF3EB8Q42721755-AB2A8539-34A7-4244-ADA5-5DEEA8820248Q42908288-DBB13EA7-1F12-4C2D-AAA8-D226A8D60C4BQ47246772-6CB53100-ADD7-46CC-910F-9049487A59E3Q57810063-6F8725DA-F8EA-48FE-8EAC-1CAA253C1625
P2860
Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Metabolism of amyloid beta pep ...... nosis, prevention and therapy.
@ast
Metabolism of amyloid beta pep ...... nosis, prevention and therapy.
@en
type
label
Metabolism of amyloid beta pep ...... nosis, prevention and therapy.
@ast
Metabolism of amyloid beta pep ...... nosis, prevention and therapy.
@en
prefLabel
Metabolism of amyloid beta pep ...... nosis, prevention and therapy.
@ast
Metabolism of amyloid beta pep ...... nosis, prevention and therapy.
@en
P1476
Metabolism of amyloid beta pep ...... nosis, prevention and therapy.
@en
P2093
Nobuhisa Iwata
Takaomi C Saido
P304
P356
10.1016/J.NEURES.2005.12.015
P577
2006-02-02T00:00:00Z